InMed (INM) director granted 3,500 options at $2.1, exp. 2030
InMed Pharmaceuticals (INM) reported a director’s Form 4 for an employee stock option grant of 3,500 options at an exercise price of $2.1 per share on Oct 17, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals (INM) reported a director’s Form 4 for an employee stock option grant of 3,500 options at an exercise price of $2.1 per share on Oct 17, 2025. The options expire on Oct 16, 2030.
Vesting is monthly in arrears: 98 options will vest on the 17th of each month for 35 months, and 70 options will vest on Oct 17, 2025, as described in the filing. Following the grant, the reporting person holds 3,500 derivative securities directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
Footnotes (1)
- F1. (1) The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date).
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did InMed (INM) disclose in the Form 4?
What is the vesting schedule for the INM options?
When do the INM options expire?
How many derivative securities are held after this transaction?
What is the transaction code on the Form 4?
Who is the reporting person for INM in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.